Abstract

In 2014, I became the Acting Director of the Women's Malignancies Branch. We are currently in the process of analyzing specimens and data from clinical trials 07C0058 - Bevacizumab and Sorafenib phase 2 in ovarian cancer; 08C0092 - Carboplatin and Olaparib in three cohort of patients: BRCA mutation carriers, high-grade serous ovarian cancer, triple negative breast cancer; and 09-C-0191 phase 1 study of bevacizumab and dasatinib. We have submitted for publication the results of clinical trial 12C0191 - SMAC-mimetic birinapant phase 2 in ovarian cancer. We currently have three clinical trials open to patient follow up (11C0022 - Pharmacokinetics of Carboplatin and Olaparib in women's cancers; 09C0019 - Bevacizumab and Dasatinib phase 1 trial; 12C0081 - Olaparib and Cederinib in ovarian cancer phase 1-2 trial). Two of our clinical trials are currently open to accrual: 14-C-0156 CHEK inhibitor for women with Triple Negative Breast Cancer and High Grade Serous Ovarian Cancer.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011584-02
Application #
9153993
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost

  Institution

Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Dull, Angie B; Wilsker, Deborah; Hollingshead, Melinda et al. (2018) Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis. Oncotarget 9:17104-17116
Annunziata, Christina M; Kohn, Elise C (2018) Clinical trials in gynecologic oncology: Past, present, and future. Gynecol Oncol 148:393-402
Del Carmen, Marcela G; Annunziata, Christina M; Rice, Laurel W (2017) The clinical trials crisis in gynecologic oncology. Gynecol Oncol 145:481-482
Wang, Ping-Yuan; Li, Jie; Walcott, Farzana L et al. (2017) Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127:132-136
Zorn, Kristin K; Annunziata, Christina M (2016) Editorial: Inhibiting PARP as a Strategic Target in Cancer. Front Oncol 6:91
Noonan, Anne M; Bunch, Kristen P; Chen, Jin-Qiu et al. (2016) Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer. Cancer 122:588-597